Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356108 | 0.84 | LMNA (0.59) | FDFT1FAAHLTA4HNR1H2NR1H3 | |
| SCHEMBL14656387 | 0.84 | LTA4H (0.57) | KMOHSP90AA1LTA4HNR1H2NR1H3 | |
| SCHEMBL4173678 | 0.83 | KMO (0.51) | KMOHSP90AA1FDFT1FAAHMRGPRX4 | |
| SCHEMBL4160110 | 0.83 | KMO (0.51) | KMOHSP90AA1FDFT1FAAHMRGPRX4 | |
| SCHEMBL16316249 | 0.83 | KMO (0.51) | KMOHSP90AA1FDFT1FAAHMRGPRX4 | |
| SCHEMBL4173672 | 0.83 | KMO (0.51) | KMOHSP90AA1FDFT1FAAHMRGPRX4 | |
| SCHEMBL358425 | 0.80 | LTA4H (0.67) | LTA4H | |
| SCHEMBL29661187 | 0.80 | LTA4H (0.67) | LTA4H | |
| SCHEMBL10547112 | 0.79 | KMO (0.51) | KMOHSP90AA1FDFT1FAAHMRGPRX4 | |
| SCHEMBL13719216 | 0.79 | KMO (0.48) | KMOHSP90AA1FDFT1FAAHCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-4366325-A | Process for the preparation of 3-phenoxy-benzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-12-28 | — | — | US | disclosed |
| EP-0028714-B1 | PROCESS FOR THE PREPARATION OF 3-PHENOXYBENZALDEHYDES | BAYER AG (DE) | 1982-09-15 | — | — | EP | disclosed |
| EP-0028714-A1 | Process for the preparation of 3-phenoxybenzaldehydes | BAYER AG (DE) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | KMO 4400/4885HSP90AA1 1693/4885FDFT1 3463/4885 |
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | KMO 2211/4885HSP90AA1 4183/4885FDFT1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.